Director of Victorian Heart Hospital South Australian Health & Med Res Inst

Printed as of 12/14/2025

Disclosures

Personal Commercial (26)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self		·	
Amgen	Research/Research Grants	Significant (>= \$5,000)	Prevention
Amgen Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
AstraZeneca	Research/Research Grants	Significant (>= \$5,000)	Prevention
AstraZeneca	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Atheronova	Research/Research Grants	Significant (>= \$5,000)	Prevention Vascular Medicine
Boehringer Ingelheim	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Cerenis	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention Vascular Medicine
Cerenis	Research/Research Grants	Significant (>= \$5,000)	Vascular Medicine Prevention
CSL Behring	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
CSL Sequiris	Consultant Fees/Honoraria	None (\$0)	Prevention
Daiichi Sankyo	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Eli Lilly	Research/Research Grants	Significant (>= \$5,000)	Prevention
Eli Lilly and Company	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
InfraReDx	Research/Research Grants	Significant (>= \$5,000)	Invasive CV Angio and Interventions
Merck Schering-Plough	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Novartis	Research/Research Grants	Significant (>= \$5,000)	Prevention
Novo Nordisk Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Omthera	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Pfizer	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Resverlogix	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Resverlogix	Research/Research Grants	Significant (>= \$5,000)	Prevention
Roche	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Sanofi-Regeneron	Research/Research Grants	Significant (>= \$5,000)	Prevention
Sanofi-Regeneron	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Takeda	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Vaxxinity	Research/Research Grants ‡ phase 1	Significant (>= \$5,000)	Prevention

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 11/19/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 11/19/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 11/19/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 11/19/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.